Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single - agent activity in a Phase I study of patients with CML with failure of prior TKI therapy

Ottmann, Oliver, Alimena, Giuliana, DeAngelo, Daniel J., Goh, Yeow-Tee, Heinrich, Michael C., Hochhaus, Andreas, Hughes, Timothy P., Mahon, Francois-Xavier, Mauro, Michael J., Minami, Hironobu, Nguyen, Marie Huong, Rea, Delphine, Steegmann, Juan Luis, Chatterjee, Arkendu, Iyer, Varsha, Martinez, Noelia, Vanasse, Gary J. and Dong-Wook, Kim 2015. ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single - agent activity in a Phase I study of patients with CML with failure of prior TKI therapy. Blood 126 (23) , 138.

Full text not available from this repository.
Item Type: Article
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
Publisher: American Society of Hematology
ISSN: 0006-4971
Last Modified: 04 Jun 2017 09:33
URI: http://orca.cf.ac.uk/id/eprint/96763

Actions (repository staff only)

Edit Item Edit Item